ASCOT LLA trial
Jump to navigation
Jump to search
Introduction
Industry funded, randomized, multicenter European trial designed to assess effects of statins in prevention of cardiovascular disease in hypertensive patients serum cholesterol < 251 mg/dL.
Lipid-lowering arm of ASCOT clinical trial.
Design:
Subjects:
- 10,000 hypertensive patients
- age 40-79 years
- serum cholesterol < 251 mg/dL (ave 213 mg/dL)
- no history of coronary artery disease
Patients assigned to receive antihypertensive(s) plus atorvastatin 10 mg or placebo.
Primary endpoint: fatal & non fatal myocardial infarction.
Results:
- trial stopped after median of 3.3 years
- significantly fewer myocardial infarctions in atorvastatin group vs placebo (100 vs 154)
- significantly fewer strokes in atorvastatin group (89 vs 121)
- at 3 years lower mean serum cholesterol 43 mg/dL (1.1 mmol/L) in atorvastatin group
More general terms
References
- ↑ Journal Watch 23(10):77, 2003 Sever PS et al, Lancet 361(Apr 5):1149, 2003 Lindhol LH & Samuelsson O, Lancet 361(Apr 5):1144, 2003